Abiomed Inc (ABMD): Michael G Howley , VP, Global Sales & Marketing of Abiomed Inc sold 200 shares on Apr 8, 2016. The Insider selling transaction was disclosed on Apr 12, 2016 to the Securities and Exchange Commission. The shares were sold at $98.80 per share for a total value of $19,759.50.
Currently the company Insiders own 10.5% of ABIOMED shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -19.22%.Institutional Investors own 92.84% of ABIOMED shares.During last six month period, the net percent change held by insiders has seen a change of -19.22%.
Shares of ABIOMED (ABMD) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -1.15 points or -1.19% at $95.1 with 3,86,370 shares getting traded. Post opening the session at $96.45, the shares hit an intraday low of $94.89 and an intraday high of $96.74 and the price vacillated in this range throughout the day. The company has a market cap of $4,036 M and the number of outstanding shares has been calculated to be 4,24,37,354 shares. The 52-week high of ABIOMED is $110.6758 and the 52-week low is $59.04.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.